Cell Metabolism Lab (GA-08), Department of Developmental Biology and Genetics (DBG), Indian Institute of Science (IISc), Bengaluru, India.
Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
Front Endocrinol (Lausanne). 2024 Mar 11;15:1330058. doi: 10.3389/fendo.2024.1330058. eCollection 2024.
Pheophorbide A, a chlorophyll-breakdown product, is primarily investigated for its anti-oxidant and anti-inflammatory activity. Recent reports on pheophorbide A have shown its potential in lowering blood glucose levels, thus leading to the exploration of its use in diabetes management. Literature has also shown its effect on enhanced insulin secretion, whereas its mechanism on glucose stimulated insulin secretion (GSIS) in pancreatic β cells remains unexplored.
and investigations were used to explore the effect of pheophorbide A on class I glucose transporters (GLUTs). studies include - Molecular docking studies and stability assessment using GROMACS. studies include - MTT assay, Glucose uptake assay, Live-cell imaging and tracking of GLUTs in presence of Pheophorbide A compared to control.
Molecular docking studies revealed better binding affinity of pheophorbide A with GLUT4 (-11.2 Kcal/mol) and GLUT1 (-10.7 Kcal/mol) when compared with metformin (-5.0 Kcal/mol and -4.9 Kcal/mol, respectively). Glucose levels are largely regulated by GLUTs where GLUT1 is one of the transporters that is ubiquitously present in human β cells. Thus, we confirmed the stability of the complex, that is, pheophorbide A-GLUT1 using GROMACS for 100 ns. We further assessed its effect on a pancreatic β cell line (INS-1) for its viability using an MTT assay. Pheophorbide A (0.1-1 µM) showed a dose-dependent response on cell viability and was comparable to standard metformin. To assess how pheophorbide A mechanistically acts on GLUT1 in pancreatic β cell, we transfected INS-1 cells with GLUT1-enhanced green fluorescent protein and checked how the treatment of pheophorbide A (0.50 µM) modulates GLUT1 trafficking using live-cell imaging. We observed a significant increase in GLUT1 density when treated with pheophorbide A (0.442 ± 0.01 µm-2) at 20 mM glucose concentration when compared to GLUT1 control (0.234 ± 0.01 µm-2) and metformin (0.296 ± 0.02 µm-2). The average speed and distance travelled by GLUT1 puncta were observed to decrease when treated with pheophorbide A. The present study also demonstrated the potential of pheophorbide A to enhance glucose uptake in β cells.
The current study's findings were validated by in-silico and cellular analyses, suggesting that pheophorbide A may regulate GLUT1 and might be regarded as a potential lead for boosting the GSIS pathway, thus maintaining glucose homeostasis.
叶啉 A 是一种叶绿素分解产物,主要因其抗氧化和抗炎活性而受到研究。最近关于叶啉 A 的报告表明,它具有降低血糖水平的潜力,从而促使人们探索其在糖尿病管理中的应用。文献还表明它对增强胰岛素分泌有影响,而其在胰岛 β 细胞葡萄糖刺激胰岛素分泌 (GSIS) 中的作用仍未得到探索。
使用分子对接研究和 GROMACS 进行稳定性评估,研究叶啉 A 对 I 类葡萄糖转运体 (GLUTs) 的影响。分子对接研究表明,与二甲双胍 (-5.0 Kcal/mol 和 -4.9 Kcal/mol) 相比,叶啉 A 与 GLUT4 (-11.2 Kcal/mol) 和 GLUT1 (-10.7 Kcal/mol) 的结合亲和力更好。葡萄糖水平主要由 GLUTs 调节,其中 GLUT1 是普遍存在于人类 β 细胞中的转运体之一。因此,我们使用 GROMACS 对复合物(即叶啉 A-GLUT1)的稳定性进行了 100 ns 的确认。我们进一步使用 MTT 测定法评估了叶啉 A 对胰岛 β 细胞系 (INS-1) 的生存能力的影响。叶啉 A(0.1-1 µM)表现出剂量依赖性的细胞活力反应,与标准二甲双胍相当。为了评估叶啉 A 在胰岛 β 细胞中如何通过 GLUT1 发挥作用,我们用 GLUT1 增强型绿色荧光蛋白转染 INS-1 细胞,并使用活细胞成像检查叶啉 A(0.50 µM)处理如何调节 GLUT1 转运。当葡萄糖浓度为 20 mM 时,与 GLUT1 对照(0.234 ± 0.01 µm-2)和二甲双胍(0.296 ± 0.02 µm-2)相比,用叶啉 A 处理时 GLUT1 密度显著增加(0.442 ± 0.01 µm-2)。用叶啉 A 处理时,GLUT1 斑点的平均速度和移动距离观察到减少。本研究还表明叶啉 A 具有增强β 细胞葡萄糖摄取的潜力。
通过计算机模拟和细胞分析验证了本研究的发现,表明叶啉 A 可能调节 GLUT1,可被视为增强 GSIS 途径的潜在先导化合物,从而维持血糖平衡。